Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie, Yuxuan Wang, Cristian Tomasetti et al. · Science Translational Medicine · 2016
Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. We used massively parallel sequencing-based assays to evaluate the ability of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective cohort of 230 patients with resected stage II colon cancer. In patients not treated with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%) patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR), 18; 95% confidence interval (CI), 7.9 to 40; P < 0.001]. In patients treated with chemotherapy, the presence of ctDNA after completion of chemotherapy was also associated with an inferior recurrence-free survival (HR, 11; 95% CI, 1.8 to 68; P = 0.001). ctDNA detection after stage II colon cancer resection provides direct evidence of residual disease and identifies patients at very high risk of recurrence.
Cited by 1,485 works. doi:10.1126/scitranslmed.aaf6219
Authors
- Jeanne Tie
- Yuxuan Wang
- Cristian Tomasetti
- Lu Li
- Simeon U. Springer
- Isaac Kinde
- Natalie Silliman
- MARK A. TACEY
- Hui‐Li Wong
- Michael Christie
- Suzanne Kosmider
- Iain Skinner
- Rachel Wong
- Malcolm Steel
- Ben Tran
- Jayesh Desai
- Ian T. Jones
- Andrew Mark Haydon
- Theresa Hayes
- Timothy Jay Price
References
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- The classification of cancer of the rectum
- Comprehensive molecular characterization of human colon and rectal cancer
- The Genomic Landscapes of Human Breast and Colorectal Cancers
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
- Circulating mutant DNA to assess tumor dynamics
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
- Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers